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Abstract. Non-motor symptoms such as neuropsychiatric and cognitive dysfunction have been found to be common in Parkinson’s
disease (PD) but the relation between such symptoms is poorly understood. We focused on alexithymia, an impairment of
affective and cognitive emotional processing, as there is evidence for its interaction with cognition in other disorders. Twenty-two
non-demented PD patients and 22 matched normal control adults (NC) were administered rating scales assessing neuropsychiatric
status, including alexithymia, apathy, and depression, and a series of neuropsychological tests. As expected, PD patients showed
more alexithymia than NC, and there was a significant association between alexithymia and disease stage. Alexithymia was
associated with performance on non-verbally mediated measures of executive and visuospatial function, but not on verbally
mediated tasks. By contrast, there was no correlation between cognition and ratings of either depression or apathy. Our findings
demonstrate a distinct association of alexithymia with non-verbal cognition in PD, implicating right hemisphere processes, and
differentiate between alexithymia and other neuropsychiatric symptoms in regard to PD cognition.
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1. Introduction
Parkinson’s disease (PD) is traditionally character-
ized as a motor disorder, but the existence of non-motor
symptoms is attracting increasing attention from clin-
icians and researchers because of their impact on pa-
tients’ quality of life. Among others, the non-motor
symptoms include cognitive dysfunction [1–4] and neu-
ropsychiatric symptoms such as apathy [5–13], depres-
sion [14–19], and alexithymia [20,21]. PD-associated
cognitive impairments have been attributed to reduced
dopaminergic innervation in the nigrostriatal andmeso-
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cortical dopaminergic systems, leading to dysfunction
of neural circuits including the basal ganglia and corti-
cal projection areas (reviewed in [3]). PET studies have
shown decreased network activity [22] and metabolic
abnormalities [23] in prefrontal and parietal brain re-
gions in PD patients with mild cognitive impairment,
consistent with the cognitive domains commonly af-
fected in PD: executive and visuospatial function [24].
Alexithymia, an impairment of affective and cog-
nitive emotional processing, is a common neuropsy-
chiatric concomitant of PD [25], with an estimated
prevalence of 21% in non-demented patients [21,26].
Dopamine depletion in brain areas critical for emotion-
al cognition, such as anterior cingulate cortex (ACC)
and orbitofrontal cortex [27,28], may underlie the man-
ifestation of alexithymia in this disorder. Though under-
studied, it has been suggested that alexithymia should
be considered and treated as an important non-motor
ISSN 0953-4180/13/$27.50  2013 – IOS Press and the authors. All rights reserved
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symptom of PD [20]. The multifaceted construct of
alexithymia is characterized by the following: a) dif-
ficulty identifying and distinguishing between feelings
and bodily sensations of emotional arousal, b) difficul-
ty describing feelings, c) reduced imaginal processes,
and d) a stimulus-bound, externally-oriented cognitive
style [29]. Alexithymia characteristics reflect deficits
in the cognitive processing and regulation of emotions,
such as the inability to apply adaptive processes for
affect regulation (e.g., modulating arousal, expressing
or suppressing emotions, and cognitive assimilation),
which may in turn contribute to the development and
course of various psychiatric and medical disorders,
such as depression and diabetes [30–32], and affect
treatment outcome [33–35].
According to a current model, alexithymia derives
from dysfunction of frontal areas [36,37], specifical-
ly the ACC and prefrontal cortex [38]. Support for
this model comes from neuroimaging studies [39–43],
which also have related alexithymia to predominant-
ly right hemisphere dysfunction. Scores on the stan-
dard measure of alexithymia, the Toronto Alexithymia
Scale (TAS-20 total), were reported to be significantly
correlated with gray matter volume of the right, but
not left, pregenual ACC in a sample of healthy older
adults [44]. In another study of normal aging, a signif-
icant correlation was found between right rostral ACC
volume and alexithymia ratings, with more advanced
age corresponding to higher alexithymia ratings and
to smaller overall right ACC total gray matter volume
in rostral and dorsal subregions as well as in the left
rostral subregion [45]. Alexithymia has also been re-
lated to right-hemisphere lesions in individuals with
stroke [46].
There is little known in regard to the relation be-
tween alexithymia and cognitive dysfunction in PD. In
one study alexithymia was associated with poor perfor-
mance on a cognitive (visuospatial) test [47]. In indi-
vidualswithHIV, which is like PD in that it affects fron-
tostriatal areas, associations were documented between
alexithymia, but not depression, and performance on
measures of executive and visuospatial function [48].
While alexithymia is often associated with depres-
sion [49–51], previous research has indicated that they
should be considered distinct constructs [52–55]. In
PD, some studies also related alexithymia and depres-
sion [26,56], while others showed that the two condi-
tions may be reliably dissociated in this disorder [20,
21], suggesting that alexithymia is at least partly inde-
pendent of depression in PD andmay be directly related
to the disease process [20].
Apathy, like alexithymia, is associated with dam-
age to the frontal lobes and disruption of the frontal-
subcortical anterior cingulate circuits [57–59]. Neu-
roimaging research has shown that the severity of ap-
athy is associated with the volume of the nucleus ac-
cumbens, one of the central structures in the anterior
cingulate frontal-subcortical circuit [60]. Apathy, like
alexithymia, also appears to be more common in pa-
tients with right- than left-hemisphere damage [9,61].
Neuroimaging research has shown that apathy is asso-
ciated with decreased gray matter volume in the right
anterior cingulate in older adults [62]. In PD, apathy
was correlated with low gray matter density in bilat-
eral inferior frontal gyrus and inferior parietal gyrus,
right cingulate and right precuneus in one study [63];
and with low volume of the right medial temporal lobe
in another study [5]. Also in PD, apathy has been re-
lated to emotional cognition, specifically the ability to
attribute emotional states to others [64]. Similarly, ap-
athy has been related to alexithymia in patients with
frontostriatal dysfunction arising from neurodegenera-
tive disease [44] and HIV [48]. The anatomical overlap
in neural networks involved in alexithymia and apathy,
together with the neuropsychological findings, raises
the question of potential overlap in the expressions of
alexithymia and apathy in PD.
The present study aimed to explore the expression
of neuropsychiatric symptoms in PD without dementia
by assessing the effect of neuropsychiatric status, and
alexithymia in particular, on cognitive function. Exam-
ining the relation between emotional processing and
cognitive function is important from both clinical and
theoretical perspectives, as it may provide insights into
the interaction of emotional and cognitive neural sys-
tems. The present study had two main aims. The first
was to explore the association between alexithymia and
cognition in PD and to consider the mechanisms un-
derlying an association. The ACC connections with the
prefrontal and parietal cortices are important for both
cognitive (executive in particular) and emotional func-
tion [65–67]. We hypothesized that alexithymia level
should be associated with cognitive dysfunction asso-
ciated with these brain areas, including attention, exec-
utive function, and visuospatial processing. To address
an ongoing debate in the literature regarding lateralized
(left vs. right hemisphere) expression of alexithymia
and follow the lead of one neuropsychological study of
PD that suggested an association between alexithymia
and cognitive abilitiesmediated by the right hemisphere
(i.e., visuospatial function) [47], in the present study
we related alexithymia to material-specific cognitive
Y. Bogdanova and A. Cronin-Golomb / Alexithymia in PD 537
domains (verbal vs. non-verbal). We also explored the
relation between cognitive performance and various as-
pects (factors) of alexithymia in PD, as neuroimaging
studies have suggested differentiation between neural
systems associated with specific aspects of alexithymia.
The second aim was to examine the potential over-
lap between alexithymia and apathy in PD. Based on
the results of imaging and behavioral studies as de-
scribed above, we hypothesized that if apathy and alex-
ithymia share common neurophysiological substrates,
there should be an association between the levels of
apathy and alexithymia. We also examined the extent
of overlap between alexithymia and apathy in regard to
their relation to cognition in PD.
2. Methods
2.1. Participants
Twenty-two consecutively-enrolled non-demented
individuals with idiopathic PD (10 men, 12 women)
and 22 normal control adults (NC) (10 men, 12 wom-
en) matched on socio-demographic variables partici-
pated in the study. All participants scored 28 or higher
on the Mini-Mental State Examination (MMSE) [68]
and were not demented. PD participants were recruited
from the ParkinsonClinic of the Department of Neurol-
ogy, Boston Medical Center and through local support
groups. NC were recruited from the community. The
research was approved by Boston University’s Institu-
tional Review Board. Participants were required to be
native speakers of English. Exclusion criteria included
co-existing cancer, serious cardiac disease, other seri-
ous chronic medical illness, prior intracranial surgery,
history of traumatic brain injury, psychiatric diagnosis
(exclusive of depression or anxiety) or neurological di-
agnoses other than PD; history of alcoholism or other
drug abuse; history of eye disease or other abnormal-
ities; and use of psychoactive medications, except for
use of antidepressants and anxiolytics in the PD group,
which are commonly prescribed. PD clinical staging
was determined by the patient’s neurologist based on
the widely used index of motor disability, the Hoehn
and Yahr scale (H&Y) [69]. All PD participants were
stages I–III (mild to moderate bilateral). The average
duration of disease was 7.8 years (SD = 3.1). PD di-
agnosis was made by patients’ neurologists, using UK
Parkinson’s Disease Society Brain Bank clinical diag-
nostic criteria [70]. Side of motor symptom onset was
obtained by patient report and fromneurologist records.
Eleven patients had initial motor symptom on the right
body side (RPD: 5 men, 6 women) and 11 had left-
side onset (LPD: 5 men, 6 women). RPD and LPD
groups did not differ in age, education, MMSE, H&Y
stage, or disease duration. There were no group dif-
ferences between male and female PD participants for
age, education, MMSE, H&Y stage, or disease dura-
tion. All PD participants received daily dopamine re-
placement therapy and /or dopamine receptor agonists.
Levodopa equivalent dosages (LED) were calculated
based on previous reports with LED: (regular levodopa
dose× 1)+ (levodopa controlled-release dose× 0.75)
+ (pramipexole dose × 67.0) + (ropinirole dose ×
16.67) + (rotigotine × 16.67) + (pergolide dose and
cabergoline dose × 67.0) + (bromocriptine dose ×
10) + ([regular levodopa dose + levodopa controlled-
release dose × 0.75] × 0.25, if taking tolcapone or
entacapone) [71]. None of the PD participants were
taking anticholinergic medications. Three were taking
some form of sleep medication. PD participants were
tested while on their anti-parkinsonian medications (in
their “on” state).
2.2. Procedure
Study participants were administered standardized
measures of neuropsychiatric functioning and a series
of standardized neuropsychologicalmeasures sensitive
to PD-associated cognitive impairments. The cognitive
tests were chosen to sample both verbal and non-verbal
domains. Because the PDandNCgroupswerematched
on age, education, and male:female ratio, we compared
and report raw scores for all tests. Before participating,
each individual provided written informed consent.
2.2.1. Neuropsychiatric status assessment
The 20-itemToronto Alexithymia Scale (TAS-20)was
administered to evaluate alexithymia [72]. It compris-
es three subscales that reflect distinct facets of alex-
ithymia: Factor 1 (difficulty identifying feelings and
distinguishing them from bodily sensations of emotion,
DIF), Factor 2 (difficulty describing feelings, DDF),
and Factor 3 (externally oriented thinking, EOT). Item
responses were rated on a five-point Likert scale rang-
ing from 1 to 5. Higher scores reflect more severe alex-
ithymia. Based on the total score, individuals are cate-
gorized as non-alexithymic (scores ranging from 20 to
51), borderline alexithymic (scores ranging from 52 to
60), or alexithymic (scores  61) [72].
Apathy was assessed using the modified 14-item Ap-
athy Scale (AS) [10,73]. Items are rated on a 0-to-3Lik-
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ert scale. Scores range from 0 to 42, with higher scores
indicative of more severe apathy. Total score was the
dependent measure. AS and its modified version were
reported to have excellent psychometric properties and
have been used to study PD [10].
The Beck Depression Inventory, Second Edition
(BDI-II) [74] is a 21-item self-report instrument that
assesses the existence and severity of symptoms of de-
pression as listed in the American Psychiatric Asso-
ciation’s Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition [DSM-IV; [75]]. There is a
four-point scale for each item ranging from0 to 3. Total
score in the range of 0–13 is considered indicative of
minimal depression, 14–19 is mild, 20–28 is moderate,
and 29–63 is severe. The BDI is considered a reliable
and valid measure of depression in PD [76].
2.2.2. Cognitive functioning assessment
The neuropsychological series included a number of
tests that we expected to be sensitive to frontostriatal
and parietal dysfunction (attention, executive function,
visuospatial ability) [3,8,48]. A focus of interest was
on the potential dissociation between correlations of
neuropsychiatric status and performance on the verbal-
ly and non-verbally mediated cognitive tests.
2.2.2.1. Verbal domain
Controlled Oral Word Association Test [77]. This is
a test of verbal fluency: (1) phonemic fluency, in which
participants were required to generate words beginning
with a particular letter (F, A, S); and (2) category flu-
ency, in which participants generate words that belong
to a particular category (Animals). Total number cor-
rect within a 60-s time period for each condition was
recorded.
Digit Span, Wechsler Memory Scale III [78], is a
measure of the efficiency of attention (Forward Span)
and working memory (Backward Span) in the verbal
domain [79]. The total score was used for the group
comparison.
Subtracting from 100 by 7 [80] is a task of sequential
arithmetic operation. A neuroimaging study demon-
strated bilateral prefrontal and posterior parietal cortex
activation during silent subtraction by sevens in healthy
adults [81]. The task is presented verbally and requires
a spoken verbal answer. Time to completion and num-
ber of errors was recorded.
2.2.2.2. Non-verbal domain
The Trail Making Test (TMT) [82] is a test of psy-
chomotor speed, attention, and executive functioning
that consists of two subtests. Trails A is a test of simple
attention and psychomotor speed, in which participants
connect numbered circles in ascending order (1-2-3,
etc.). Trails B is a measure of combined visual search,
psychomotor speed, and cognitive flexibility, assessing
the ability to shift and maintain the response set. Par-
ticipants sequentially alternate between alphanumeric
sequences (1-A-2-B, etc.). Time to completion and
number of errors were recorded.
Raven’sColouredProgressiveMatrices (RCPM) [83].
This is a measure of visuospatial skills and reasoning
ability. The task is to choose one of six possible com-
pletions of an incomplete pattern matrix. Total score
(the number correct out of 36 items) was recorded.
Clock reading test [80]. Participants are asked to
identify and mark the time shown on each of the
10 clocks presented on a standard paper. Time to com-
pletion and number of errors were recorded.
Visual symbol search test [84] provides a measure of
visual scanning abilities and sustained attention. Par-
ticipants search and cancel the target symbol in the
non-verbal array. Time to completion was recorded.
Boston Visuospatial Quantitative Battery (BVSQB;
[85]). On the Drawing to Command subtest, the partic-
ipant is required to draw six objects, one at a time. To-
tal number of correct points was recorded. Right-Left
Orientation subtest requires the identification of right
and left on 20 different body parts and objects drawn in
various positions. The number of errors was recorded.
2.2.3. Statistical analyses
To analyze differences between the PD and NC
groups, independent samples t-tests (2-tailed) were
used. Alpha was set to 0.01 to account for multiple
comparisons. Analyses of performance of men and
women in the PD and NC groups revealed no signifi-
cant differences in neuropsychological profile or mood
ratings, and data were accordingly collapsed across
these subgroups. Pearson correlations were performed
to examine associations between neuropsychiatric sta-
tus and neuropsychological performance. Linear re-
gression analyses were then performed to examine the
role of neuropsychiatric and neuropsychological fac-
tors in predicting alexithymia in PD, with alexithymia
as the dependent variable and neuropsychiatric test
scores (apathy and depression) and neuropsychologi-
cal test scores (those correlated with alexithymia) as
independent variables.
3. Results
This study used a mixed design, with each partici-
pant receiving all assessments. The results are divided
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Table 1
Demographic and clinical characteristics of PD and NC participants.
Means (SD) are reported unless otherwise indicated
NC PD p
N 22 22
Age (years) 61.0 (7.8) 61.8 (6.1) ns
Education (years) 16.6 (1.8) 15.6 (2.3) ns
Disease duration (years) n/a 7.8 (3.1)
Hoehn and Yahr stage∧ n/a 2 (1–3)
LED n/a 626.3 (258.5)
Dopamine agonist (%) n/a 68.1%
Neuropsychiatric status:
TAS-20 total 32.1 (5.8) 42.2 (10.3) 0.0001
TAS-20 Factor 1 9.9 (3.2) 12.3 (4.7) ns
TAS-20 Factor 2 8.2 (2.5) 11.6 (3.5) 0.001
TAS-20 Factor 3 14.4 (4.2) 18.2 (5.1) 0.009
AS total 7.8 (4.0) 8.1 (4.1) ns
BDI-II total 4.2 (3.9) 6.9 (3.6) ns
∧Median (range); n/a: not applicable; LED: Levodopa equivalent
dosage; TAS-20: Toronto Alexithymia Scale-20; AS: Apathy Scale;
BDI-II: Beck Depression Inventory-II.
into two sections. The first section presents findings re-
garding the effects of PD on neuropsychiatric status and
cognitive function, and the second section relates neu-
ropsychiatric status to cognitive performance, specifi-
cally to the verbal vs. non-verbal cognitive domains.
3.1. Effects of PD on neuropsychiatric status and
cognitive function
3.1.1. Neuropsychiatric status
Independent groups t-tests revealed that the PD par-
ticipants reported significantly higher alexithymia lev-
els (TAS-20 total) than the NC group. There were no
group differences in depression or apathy level, though
there was a trend toward more depression in the PD
group (Table 1). Comparison of the LPD and RPD
subgroups revealed no significant differences in alex-
ithymia, apathy or depression levels [all p′s > 0.61].
We also explored the relation between alexithymia
factors and both apathy and depression using Pearson
correlations (two-tailed). Alexithymia ratings (TAS-
20) correlated with apathy and depression. Specifical-
ly, F1 was associated with depression [r = 0.36, p <
0.018], whereas F3 was associated with apathy [r =
0.36, p < 0.017] in PD. We observed a trend toward a
similar pattern of correlations (F1 with depression and
F3 with apathy level) [p′s < 0.052] in NC.
3.1.2. Cognitive performance
To examine whether the PD group exhibited cogni-
tive deficits compared to the NC group, we conducted
independent groups t-tests. The PD group performed
Table 2
Neuropsychological performance. Raw score mean values (SD)
NC PD p
Verbal domain
FAS total 53.5 (15.5) 42.1 (8.8) 0.005
Animals total 21.8 (3.4) 19.4 (4.4) ns
Digit span forward total 12.2 (2.2) 11.0 (1.9) ns
Digit span backward total 8.9 (2.6) 6.7 (2.2) 0.004
100-7 time (sec) 43.8 (22.4) 69.5 (38.0) 0.01
100-7 errors 1.1 (1.6) 2.0 (1.8) ns
Non-Verbal domain
TMT A errors 0.0 (0.0) 0.1 (0.2) ns
TMT B errors 0.3 (0.6) 0.5 (1.2) ns
RCPM total 34.1 (2.3) 31.6 (3.7) 0.01
Clock reading time (sec) 47.4 (18.4) 62.2 (19.9) 0.01
Clock reading errors 0.9 (1.5) 2.1 (7.1) ns
Visual symbol search time (sec) 83.2 (23.4) 133.6 (75.8) 0.005
BVSQB drawing total correct 11.0 (2.0) 9.4 (2.1) 0.01
BVSQB right-left errors 3.9 (2.2) 5.2 (3.1) ns
FAS: Controlled Oral Word Association Test (F, A, S); TMT:
Trail Making Test; RCPM: Raven’s Coloured Progressive Matrices;
BVSQB: Boston Visuo-spatial Quantitative Battery.
more poorly than the NC group on a number of tests, as
expected. Significant group differences were observed
on verbal and non-verbal measures of executive and
visuospatial functioning (see Table 2).
3.2. Relation between neuropsychiatric status and
cognitive performance
To explore the nature of the relation between alex-
ithymia and lateralized cognitive functions in PD, we
performed Pearson correlations between alexithymia
factors and neuropsychological performance in the ver-
bal and non-verbal domains.Becausewe expectedmore
severe alexithymia to be associated with poorer execu-
tive function and visuospatial abilities, one-tailed tests
were used. To achieve a reasonable balance between
Type I and Type II errors and to allow the examination
of potential relations among variables, we adopted a
more conservative significance level of 0.025. This ad-
justment was made for similar reasons in our previous
study of alexithymia in another frontostriatal disorder,
HIV [48]. As predicted, alexithymia was associated
with performance on a number of non-verbally mediat-
ed executive function and visuospatial measures [TMT
A, TMT B, Clock Reading Test, Visual Symbol Search,
and BVSQB Drawing Test] (Table 3). By contrast there
were no significant correlations between alexithymia
and performance on verbally mediated neuropsycho-
logical measures (all r′s < 0.4; all p′s > 0.1). We
found no significant correlations between alexithymia
and neuropsychological performance in the NC group
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Table 3
Correlations between alexithymia factor scores and performance on
non-verbal neuropsychological tests in PD
TAS-20 TAS-20 TAS-20
Factor 1 Factor 2 Factor 3
TMT A errors 0.667*** ns ns
TMT B errors ns ns 0.529**
RCPM total ns ns ns
Clock reading errors ns ns 0.435*
Visual symbol search time ns 0.434* ns
BVSQB drawing total correct −0.535∗∗ ns ns
BVSQB right-left errors 0.523** ns ns
TAS-20: Toronto Alexithymia Scale-20; Factor 1: difficulty iden-
tifying feelings; Factor 2: difficulty describing feelings; Factor 3:
externally oriented thinking; FAS: Controlled Oral Word Association
Test (F, A, S); TMT: Trail Making Test; RCPM: Raven’s Coloured
Progressive Matrices; BVSQB: Boston Visuo-spatial Quantitative
Battery; Note: There were no significant correlations between alex-
ithymia factor scores and performance on neuropsychological tests
in the verbal domain. *p < 0.25, **p < 0.01, **p < 0.001.
(all r′s < 0.3; all p′s > 0.15). There were no cor-
relations between apathy (AS) or depression (BDI-II)
ratings and neuropsychological performance for either
group (all r′s < 0.3; all p′s > 0.17).
To further examine the role of neuropsychiatric and
neuropsychological factors in predicting alexithymia
(TAS-20 total) in PD,we performedmultiple regression
analyses. The first variable entered into the equation
was apathy (AS) [slope = 0.542, R2 = 0.294, t(20)=
2.4, p = 0.03], indicating an expected increase of 0.54
in TAS-20 total score for each point increase on AS.
In the second step, TMT A (errors) was entered and
significantly contributed to predicting the level of alex-
ithymia [slope = 0.763, R2 change = 0.289, t(19) =
3.0, p = 0.01]. Patients who had more errors on TMT
A showed a higher alexithymia level, with expected
increase of 0.76 for each point increase on TMT A
errors.
We also assessed the association between degree
of alexithymia and disease stage (H&Y) using multi-
ple Spearman’s correlations (two-tailed). Alexithymia
ratings significantly correlated with disease stage as
shown for the overall alexithymia rating (TAS-20 total:
r = 0.56, p < 0.020) and for F3 specifically (exter-
nally oriented thinking) (r = 0.59, p < 0.013). By
contrast, there were no significant correlations between
H&Y stage and severity of apathy (AS) or depression
(BDI-II) (all r′s < 0.39; all p′s > 0.12).
4. Discussion
We examined the effect of PD on alexithymia and
its relation to cognition in non-demented individuals
with PD. First, as expected, we found the expected
PD-related deficits in verbal and non-verbal cognitive
domains, including attention, executive function and
visuospatial function, which is reflective of frontostri-
atal and parietal dysfunction associated with the dis-
order. Second, also as predicted, PD patients reported
significantly higher levels of alexithymia than the NC
group. The group differences applied to the total alex-
ithymia score and to two of the three alexithymia pro-
cessing components, F2 (difficulty describing feelings)
and F3 (externally oriented thinking). The extent of
alexithymia and each of its processing components (F1,
F2, and F3) but not the extent of depression or apathy,
significantly correlated with performance on neuropsy-
chological measures of attention, executive and visu-
ospatial function in this sample. There was a differen-
tial association between alexithymia and performance
of tests in the non-verbal, but not the verbal, cognitive
domain, supporting our hypothesis that alexithymia is
associated with cognitive deficits mediated predomi-
nantly by the right hemisphere. The results are in ac-
cord with those of a study that showed an association of
alexithymia and performance on a visuospatial task in a
hospitalized non-demented PD patient sample [47]. To
our knowledge, ours is the first study to demonstrate a
differential association of alexithymia and apathy with
cognitive dysfunction in PD in relation to the lateral-
ized cognitive domains. While there was a significant
association between alexithymia factors, apathy and
depression in PD, neither apathy nor depression level
correlated with cognitive performance.
4.1. Potential brain substrates of alexithymia in PD
The extent of alexithymia significantly correlated
with attention, executive and visuospatial function,
cognitive domains associated with frontostriatal and
parietal pathology. This finding supports the current
“frontal” alexithymia model, which postulates that
alexithymia is the result of dysfunctional mechanisms
in the frontal cortex [36–38].The visuospatial cognitive
domain reflecting parietal dysfunction is also affected
by PDandwas associatedwith alexithymia in our study.
The ACC connections with the prefrontal and parietal
cortex are important for both cognitive and emotional
function [65–67], which may explain the significant re-
lation between visuospatial dysfunction and the extent
of alexithymia in PD.
4.2. Apathy and alexithymia in PD
Previous imaging and behavioral research (reviewed
in the Introduction) have suggested that apathy and
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alexithymia may share some common neurophysiolog-
ical substrates within frontostriatal circuits, and related
apathy and alexithymia to right-hemisphere dysfunc-
tion. We found that apathy and alexithymia differential-
ly correlated with performance on neuropsychological
measures. Whereas alexithymia was significantly as-
sociated with performance on non-verbal measures of
executive function and visuospatial ability, apathy was
not associated with performance on any of the tasks.
The fact that apathy and alexithymia can be dissociated
in PD implies that they have at least partially distinct
neural substrates within frontostriatal circuits.
The observed dissociation between the two neu-
ropsychiatric conditions in relation to cognition sug-
gests at least two potential interpretations: (1) the un-
derlying neural substrates for apathy and alexithymia
are differentially affected by PDneuropathological pro-
cesses; (2) it was too early in the course of the disease
to detect the apathy-associated changes in our sample.
In line with this argument, we found no differences in
apathy levels between our non-demented PD and NC
groups, which is consistent with the notion that apathy
may be a reflection of more advanced (moderate to se-
vere) stage of PD [25]. There was, however, a signif-
icant correlation between apathy level and severity of
alexithymia (F3) in our sample. Previous neuroimag-
ing research in healthy older adults has found a sig-
nificant correlation between right rostral ACC volume
and alexithymia ratings (TAS-20) for both total score
and F3 [45]. Taken together, these findings suggest a
potential overlap in the neural substrates (the rostral
subregion of ACC) of apathy and alexithymia, specific
to F3.
4.3. Depression and alexithymia in PD
We found no significant group difference between
PD and NC for depression, though there was a trend
for the PD group to be more depressed. The severity of
depression correlated with alexithymia level (TAS-20,
F1) but did not correlate with performance on any of
the cognitive tests, meaning that the neuropsychologi-
cal abnormalities observed in our sample could not be
attributed to depression.
The results of multiple regression analyses further
clarified the association between alexithymia, apathy
and depression in PD. We found that apathy, but not de-
pression, predicted higher levels of alexithymia. These
findings are consistent with previous studies that indi-
cated that although alexithymia may be associated with
depression, these neuropsychiatric conditions can be
dissociated in patients with PD [20,21].
Of note, in contrast to what was found in our PD
group, in our healthy control group there were no corre-
lations between alexithymia (or apathy or depression)
and performance on the neuropsychological measures
in NC group in our study. It is possible that the interac-
tion between the processing componentsof alexithymia
and cognitive dysfunction occurs only in the presence
of cognitive deficits. These results are consistent with
our findings of a significant correlation between alex-
ithymia and cognition in patients with HIV but not in
their matched healthy control group [48].
4.4. PD and the individual processing components of
alexithymia
We explored the association between cognition and
the individual processing components of alexithymia
in PD, as neuroimaging and behavioral studies have
suggested distinct neural mechanisms underlying the
components. In one study of normal aging, there was a
significant correlation between right rostral ACC vol-
ume and alexithymia ratings on TAS-20 F3 (External-
ly Oriented Thinking, EOT) [45]. These findings sug-
gested that deterioration in the rostral subregion of the
ACC with age may contribute to alexithymia, and more
specifically to F3. In a study of patients with stroke, F1,
Difficulty Identifying Feelings (DIF), and F2, Difficul-
ty Describing Feelings (DDF), were related to right-
hemisphere lesions [46]. Though limited in number,
these studies providedevidence that individual process-
ing components of alexithymia may be associated with
distinct brain regions. Specifically, F3 is thought to de-
pend on the rostral ACC. Our results support this no-
tion, as we observed group differences between PD and
NC on F3 but not F1. See Bogdanova et al. [48] for fur-
ther consideration of the role of the ACC in emotional
cognition.
Dissociations between cognitive and affective as-
pects of alexithymia (reflected by alexithymia factors)
have been reported previously in clinical and non-
clinical populations [86]. F1 (DIF) reflects the affective
dimension of alexithymia, and was found to be strong-
ly associated with depression ratings in a clinically de-
pressed group [87], which is consistent with our find-
ings. F3 (EOT, considered the cognitive component)
was found to be significantly associated with smaller
rostral ACC volume in healthy older adults [45]; with
diagnosis of obsessive-compulsive disorder, a fronto-
striato-thalamocortical disorder associated with dys-
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function of the orbitofrontal cortex, ACC, thalamus
and caudate nucleus [87]; and with cognitive perfor-
mance in another frontostriatal disorder, HIV [48]. In
the present study of PD, F3 was likewise associated
with cognitive performance, and with apathy level. F2,
by contrast, was associated with only one (visuospatial)
measure in our study, similar to the observation report-
ed in the HIV study, in which F2 was related to only a
subset of non-verballymediated tasks [48], and consis-
tent with an earlier report of F2 being related to right-
hemisphere lesions [46]. We also observed dissocia-
tions between alexithymia factors and other neuropsy-
chiatric symptoms. Specifically, apathywas significant-
ly associated with F3 alone, whereas depression was
associated with F1 alone, and F2 did not correlate with
depression or apathy. Taken together, these findings
provide further evidence for the possibility of anatomi-
cally and functionally distinct neural substrates for the
individual processing components of alexithymia.
4.5. Neuropsychiatric status and disease stage
Our results indicated a specific association be-
tween neuropsychiatric status and disease stage in non-
demented PD. The severity of alexithymia (TAS total
and F3 ratings), but not apathy or depression, were sig-
nificantly correlated with the Hoehn and Yahr index of
disease stage. It should be noted that our sample was
restricted to individuals with mild to moderate PD, in
stages I to III of the disease.
4.6. Study limitations
Our sample of PD patients, although large enough to
reveal significant differences on the various measures
in relation to the control group, was too small to allow
us to investigate potential subgroup effects, such as by
side of PD motor onset, type of motor symptom at onset
(tremor vs. other), or interactions with gender. Our PD
group included approximately equal numbers of those
with LPD and RPD as well as of men and women,
but there was insufficient power to explore potential
subgroupeffects in any depth. Also, as noted above,we
restricted the study to individualswithmild to moderate
PD without dementia. Those with more severe disease,
with or without dementia, may show a different pattern
of results in regard to neuropsychiatric status in general
and its relation to cognition in particular.
4.7. Implications
The identification and treatment of alexithymia in
patients with PD is very important, as alexithymia-
related deficits in cognitive processing and the regu-
lation of emotions have been shown to negatively af-
fect treatment outcome in othermedical and psychiatric
disorders. Apathy is another key symptom to address
in PD, as it can have significant impact on quality of
life and patient disability [88,89]. Apathy level but not
depression was associated with alexithymia severity in
our study. Alexithymia and apathy are treatable condi-
tions, and timely screening and intervention may pro-
tect the quality of life and reduce disability in individu-
als with PD. Our results indicated a correlation of alex-
ithymia and disease stage, even in this relatively mildly
impaired PD sample (non-demented, Hoehn and Yahr
stages I to III only). Longitudinal studies are needed
to investigate the temporal dynamics and change in the
expression of these neuropsychiatric deficits associated
with PD progression, and evaluate the effect of treat-
ment of these neuropsychiatric conditions on cognitive
function and quality of life in PD.
Acknowledgements
This work was supported in part by the Rehabili-
tation Research and Development Service of the De-
partment of Veterans Affairs, and by grants to Y. Bog-
danova (NIH F31 NS052131) and A. Cronin-Golomb
(R01NS067128 and R21 NS043730) from the Nation-
al Institute of Neurological Disorders and Stroke. We
thank Dr. Sandy Neargarder for expert advice on statis-
tical analyses; Mirella Diaz-Santos, M.A., and Maria
Valmas, M.A., for assistance with data collection; and
Sarah M. Kark, B.S., for assistance with manuscript
preparation. The authors have no conflicts of interest
to disclose.
References
[1] Zgaljardic DJ, Borod JC, Foldi NS, Mattis P. A review of
the cognitive and behavioral sequelae of Parkinson’s disease:
relationship to frontostriatal circuitry. Cogn Behav Neurol.
2003; 16(4): 193-210.
[2] Amick MM, Schendan HE, Ganis G, Cronin-Golomb A. Fron-
tostriatal circuits are necessary for visuomotor transforma-
tion: Mental rotation in Parkinson’s disease. Neuropsycholo-
gia. 2006; 44(3): 339-349.
[3] Cronin-GolombA. Parkinson’s disease as a disconnection syn-
drome. Neuropsychol Rev. 2010; 20(2): 191-208.
[4] Davidsdottir S, Wagenaar R, Young D, Cronin-Golomb A.
Impact of optic flow perception and egocentric coordinates on
veering in Parkinson’s disease. Brain. 2008; 131(11): 2882-
2893.
Y. Bogdanova and A. Cronin-Golomb / Alexithymia in PD 543
[5] Isella V, Melzi P, Grimaldi M, Iurlaro S, Piolti R, Ferrarese
C, et al. Clinical, neuropsychological, and morphometric cor-
relates of apathy in Parkinson’s disease. Mov Disord. 2002;
17(2): 366-371.
[6] Pluck GC, Brown RG. Apathy in Parkinson’s disease. J Neurol
Neurosurg Psychiatry. 2002; 73(6): 636-642.
[7] Kirsch-Darrow L, Fernandez HH, Marsiske M, Okun MS,
Bowers D. Dissociating apathy and depression in Parkinson
disease. Neurology. 2006; 67(1): 33-38.
[8] Bogdanova Y, Cronin-Golomb A. Neurocognitive correlates
of apathy and anxiety in Parkinson’s disease. Parkinsons Dis.
2012; 2012.
[9] Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tand-
berg E, et al. Range of neuropsychiatric disturbances in pa-
tients with Parkinson’s disease. J Neurol Neurosurg Psychia-
try. 1999; 67(4): 492-496.
[10] Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P,
Leiguarda R, Robinson RG. Reliability, validity, and clinical
correlates of apathy in Parkinson’s disease. J Neuropsychiatry
Clin Neurosci. 1992; 4(2): 134-139.
[11] Starkstein SE. The riddle of psychiatric disorders in Parkinson
disease: from phenomenology to treatment. Am J Geriatr
Psychiatry. 2012; 20(2): 99-103.
[12] Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms
of patients with progressive supranuclear palsy and Parkin-
son’s disease. J Neuropsychiatry Clin Neurosci. 2001; 13(1):
42-49.
[13] Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller
BL, Craig AH, et al. Apathy is not depression. J Neuropsychi-
atry Clin Neurosci. 1998; 10(3): 314-319.
[14] Leentjens AFG. Depression in Parkinson’s disease: conceptu-
al issues and clinical challenges. J Geriatr Psychiatry Neurol.
2004; 17(3): 120-126.
[15] McDonald WM, Richard IH, DeLong MR. Prevalence, etiol-
ogy, and treatment of depression in Parkinson’s disease. Biol
Psychiatry. 2003; 54(3): 363-375.
[16] Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AFG.
A systematic review of prevalence studies of depression in
Parkinson’s disease. Mov Disord. 2008; 23(2): 183-189.
[17] Cimino CR, Siders CA, Zesiewicz TA. Depressive symptoms
in Parkinson disease: degree of association and rate of agree-
ment of clinician-based and self-report measures. J Geriatr
Psychiatry Neurol. 2011; 24(4): 199-205.
[18] Kirsch-Darrow L, Marsiske M, Okun MS, Bauer R, Bowers
D. Apathy and depression: separate factors in Parkinson’s
disease. J Int Neuropsychol Soc. 2011; 17(6): 1058-1066.
[19] Santangelo G, Vitale C, Trojano L, Longo K, Cozzolino A,
Grossi D, et al. Relationship between depression and cogni-
tive dysfunctions in Parkinson’s disease without dementia. J
Neurol. 2009; 256(4): 632-638.
[20] Assogna F, Palmer K, Pontieri FE, Pierantozzi M, Stefani
A, Gianni W, et al. Alexithymia Is a Non-Motor Symptom
of Parkinson Disease. Am J Geriatr Psychiatry. 2012; 20(2):
133-141.
[21] Costa A, Peppe A, Carlesimo GA, Salamone G, Caltagirone C.
Prevalence and Characteristics of Alexithymia in Parkinson’s
Disease. Psychosomatics. 2010; 51(1): 22-28.
[22] Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M,
et al. Changes in network activity with the progression of
Parkinson’s disease. Brain. 2007; 130(Pt 7): 1834-1846.
[23] Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg
D. Metabolic abnormalities associated with mild cognitive
impairment in Parkinson disease. Neurology. 2008; 70(16 Pt
2): 1470-1477.
[24] Huber SJ, Bornstein RA, editors. Neuropsychological evalu-
ation of Parkinson’s disease. New York: Oxford University
Press; 1992.
[25] Poletti M, De Rosa A, Bonuccelli U. Affective symptoms and
cognitive functions in Parkinson’s disease. J Neurol Sci. 2012;
317(1–2): 97-102.
[26] Costa A, Peppe A, Carlesimo GA, Pasqualetti P, Caltagirone
C. Alexithymia in Parkinson’s disease is related to severity of
depressive symptoms. Eur J Neurol. 2006; 13(8): 836-841.
[27] Bermond B, Vorst HC, Moormann PP. Cognitive neuropsy-
chology of alexithymia: implications for personality typology.
Cogn Neuropsychiatry. 2006; 11(3): 332-360.
[28] Lane RD. Neural Correlates of Conscious Emotional Experi-
ence. In: Lane RD, Nadel L, editors. Cognitive Neuroscience
of Emotion. New York: Oxford University Press; 2000. p.
359–360.
[29] Bagby RM, Taylor GJ. Affect dysregulation and alexithymia.
In: Taylor GJ, Bagby RM, Parker JDA, editors. Disorders
of affect regulation Alexithymia in medical and psychiatric
illness. Cambridge (UK): Cambridge University Press; 1997;
pp. 26-45.
[30] Lumley MA, Stettner L, Wehmer F. How are alexithymia and
physical illness linked? A review and critique of pathways. J
Psychosom Res. 1996; 41(6): 505-518.
[31] Lumley MA, Neely LC, Burger AJ. The Assessment of Alex-
ithymia in Medical Settings: Implications for Understanding
and Treating Health Problems. J Pers Assess. 2007; 89(3):
230-246.
[32] Taylor GJ, Bagby RM, Parker JD. Disorders of affect regu-
lation: Alexithymia in medical and psychiatric illness. New
York: Cambridge University Press; 1997.
[33] Ogrodniczuk JS, Piper WE, JoyceAS. Effect of alexithymia on
the process and outcome of psychotherapy: a programmatic
review. Psychiatry Res. 2011; 190(1): 43-48.
[34] Parker JD, Keefer KV, Taylor GJ, Bagby RM. Latent struc-
ture of the alexithymia construct: a taxometric investigation.
Psychol Assess. 2008; 20(4): 385-396.
[35] Porcelli P, Tulipani C, Maiello E, Cilenti G, Todarello O.
Alexithymia, coping, and illness behavior correlates of pain
experience in cancer patients. Psychooncology. 2007; 16(7):
644-650.
[36] Davidson RJ, Ekman P, Saron CD, Senulis JA, Friesen WV.
Approach-withdrawal and cerebral asymmetry: emotional ex-
pression and brain physiology. I. J Pers Soc Psychol. 1990;
58(2): 330-341.
[37] Gainotti G. Disorders of emotions and affect in patients with
unilateral brain damage. In: Boller F, Grafman J, editors.
Handbook of Neuropsychology. Amsterdam: Elsevier; 1989;
pp. 345-358.
[38] Lane RD, Ahern GL, Schwartz GE, Kaszniak AW. Is alex-
ithymia the emotional equivalent of blindsight? Biol Psychi-
atry. 1997; 42(9): 834.
[39] Borsci G, Boccardi M, Rossi R, Rossi G, Perez J, Bonetti M,
et al. Alexithymia in healthy women: A brain morphology
study. J Affect Disord. 2009; 114(1–3): 208-215.
[40] Gu¨ndel H, Lopez-Sala A, Ceballos-Baumann AO, Deus J,
Cardoner N, Marte B. Alexithymia correlates with the size
of the right anterior cingulate. Psychosom Med. 2004; 56(6):
609-610.
[41] Huber M, Herholz K, Habedank B, Thiel A, Muller-Kuppers
M, Ebel H, et al. Different patterns of regional brain activation
during emotional stimulation in alexithymics in comparison
with normal controls. Psychother Psychosom Med Psychol.
2002; 52(11): 469-478.
544 Y. Bogdanova and A. Cronin-Golomb / Alexithymia in PD
[42] Kano M, Fukudo S, Gyoba J, Kamachi M, Tagawa M,
MochizukiH. Specific brain processing of facial expressions in
people with alexithymia: an H215O-PET study. Brain. 2003;
126(6): 1474-1484.
[43] Karlsson H, Naatanen P, Stenman H. Cortical activation in
alexithymia as a response to emotional stimuli. Br J Psychiatry.
2008; 192(1): 32-38.
[44] Sturm VE, Levenson RW. Alexithymia in neurodegenerative
disease. Neurocase. 2011; 17(3): 242-250.
[45] Paradiso S, Vaidya JG, McCormick LM, Jones A, Robinson
RG. Aging andAlexithymia: AssociationWithReducedRight
Rostral Cingulate Volume. Am J Geriatr Psychiatry. 2008;
16(9): 760-769.
[46] Spalletta G, Pasini A, Costa A, De Angelis D, Ramundo N,
Paolucci S, et al. Alexithymic Features in Stroke: Effects of
Laterality and Gender. Psychosom Med. 2001; 63(6): 944-
950.
[47] Costa A, Peppe A, Carlesimo GA, Salamone G, Caltagirone C.
Neuropsychological correlates of alexithymia in Parkinson’s
disease. J Int Neuropsychol Soc. 2007; 13(06): 980-992.
[48] Bogdanova Y, Dı´az-Santos M, Cronin-Golomb A. Neurocog-
nitive correlates of alexithymia in asymptomatic individuals
with HIV. Neuropsychologia. 2010; 48(5): 1295-1304.
[49] Honkalampi K, Hintikka J, Saarinen P, Lehtonen J, Viinamaki
H. Is alexithymia a permanent feature in depressed patients?
Psychother Psychosom. 2000; 69(6): 303-308.
[50] Saarija¨rvi S, Salminen JK, Toikka TB. Alexithymia and de-
pression: A 1-year follow-up study in outpatients with major
depression. J Psychosom Res. 2001; 51(6): 729-733.
[51] Mu¨ller J, Bu¨hner M, Ellgring H. Relationship and Differential
Validity of Alexithymia and Depression: A Comparison of
the Toronto Alexithymia and Self-Rating Depression Scales.
Psychopathology. 2003; 36(2): 71-77.
[52] Parker JD,BagbyRM,TaylorGJ.Alexithymia anddepression:
Distinct or overlapping constructs? Compr Psychiatry. 1991;
32(5): 387-394.
[53] Wise TN, Jani NN, Kass E, et al. Alexithymia: relationship
to severity of medical illness and depression. Psychother Psy-
chosom. 1988; 50(2): 68-71.
[54] Wise TN, Mann LS, Hill B. Alexithymia and depressed mood
in the psychiatric patient. Psychother Psychosom. 1990; 54(1):
26-31.
[55] Wood RL, Williams C. Neuropsychological correlates of or-
ganic alexithymia. J Int Neuropsychol Soc. 2007; 13(3): 471-
479.
[56] Poletti M, Frosini D, Pagni C, Lucetti C, Del Dotto P, Tognoni
G, et al. Alexithymia may modulate decision making in pa-
tients with de novo Parkinson’s disease. Funct Neurol. 2011;
26(3): 127-131.
[57] Cummings JL. Frontal-subcortical circuits and human behav-
ior. Arch Neurol. 1993; 50(8): 873-880.
[58] Tekin S, Cummings JL. Frontal-subcortical neuronal circuits
and clinical neuropsychiatry: an update. J Psychosom Res.
2002; 53(2): 647-654.
[59] Levy R, Dubois B. Apathy and the Functional Anatomy of
the Prefrontal Cortex – Basal Ganglia Circuits. Cereb Cortex.
2006; 16(7): 916-928.
[60] Paul RH, BrickmanAM, NaviaB, HinkinC, Malloy PF, Jeffer-
son AL, et al. Apathy is associated with volume of the nucleus
accumbens in patients infected with HIV. J Neuropsychiatry
Clin Neurosci. 2005; 17(2): 167-171.
[61] McAllister TW. Apathy. Semin Clin Neuropsychiatry. 2000;
5(4): 275-282.
[62] Lavretsky H, Ballmaier M, Pham D, Toga A, Kumar A. Neu-
roanatomical characteristics of geriatric apathy and depres-
sion: a magnetic resonance imaging study. Am J Geriatr Psy-
chiatry. 2007; 15(5): 386-394.
[63] Reijnders JS, Scholtissen B, Weber WE, Aalten P, Verhey
FR, Leentjens AF. Neuroanatomical correlates of apathy in
Parkinson’s disease: A magnetic resonance imaging study
using voxel-based morphometry. Mov Disord. 2010; 25(14):
2318-2325.
[64] Santangelo G, Vitale C, Trojano L, Errico D, Amboni M,
Barbarulo AM, et al. Neuropsychological correlates of theory
ofmind in patientswith early Parkinson’s disease.MovDisord.
2012; 27(1): 98-105.
[65] Bush G, Luu P, Posner MI. Cognitive and emotional influences
in anterior cingulate cortex. Trends Cogn Sci. 2000; 4(6):
215-222.
[66] Nieuwenhuis S, Ridderinkhof KR, Blom J, Band GP, Kok
A. Error-related brain potentials are differentially related to
awareness of response errors: evidence from an antisaccade
task. Psychophysiology. 2001; 38(5): 752-760.
[67] Posner MI, DiGirolamo GJ. Executive attention: Conflict,
target detection and cognitive control. In: Parasuraman R,
editor. The attentive brain. Cambridge (MA):MITPress; 1998;
pp. 401-423.
[68] Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”.
A practical method for grading the cognitive state of patients
for the clinician. J Psychiatr Res. 1975; 12(3): 189-198.
[69] Hoehn MM, Yahr MD. Parkinsonism: onset, progression and
mortality. Neurology. 1967; 17(5): 427-442.
[70] Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clin-
ical diagnosis of idiopathic Parkinson’s disease: a clinico-
pathological study of 100 cases. J Neurol Neurosurg Psychia-
try. 1992; 55(3): 181-184.
[71] Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen
JP. Occurrence and clinical correlates of REM sleep behaviour
disorder in patients with Parkinson’s disease over time. J Neu-
rol Neurosurg Psychiatry. 2008; 79(4): 387-391.
[72] Bagby RM, Parker JDA, Taylor GJ. The twenty-item Toronto
Alexithymia Scale-I. Item selection and cross-validation of the
factor structure. J Psychosom Res. 1994; 38(1): 23-32.
[73] Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and
validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;
38(2): 143-162.
[74] Beck AT, Steer RA, Brown GK. Beck Depression Inventory-II.
San Antonio (TX): The Psychological Corporation; 1996.
[75] American Psychiatric Association. Diagnostic and Statistical
Manual of MentalDisorders. 4th ed., Washington (DC):Amer-
ican Psychiatric Association; 1994.
[76] LevinBE, LlabreMM,WeinerWJ. Parkinson’s disease andde-
pression: psychometric properties of the Beck Depression In-
ventory. J Neurol Neurosurg Psychiatry. 1988; 51(11): 1401-
1404.
[77] Benton AL, Hamsher K. Multilingual Aphasia Examination.
2nd ed., Iowa City (IA): AJA Associates, Inc; 1989.
[78] Wechsler D. The Wechsler Memory Scale-III Manual. 3rd ed.,
San Antonio (TX): The Psychological Corporation; 1997.
[79] Lezak MD, Howieson DB, Loring DW. Neuropsychological
assessment. 4th ed., New York: Oxford University Press;
2004.
[80] Luria AR. Higher Cortical Functions in Man. Moscow:
Moscow University Press; 1962.
[81] Rueckert L, Lange N, Partiot A, Appollonio I, Litvan I, Le
Bihan D, et al. Visualizing cortical activation during mental
Y. Bogdanova and A. Cronin-Golomb / Alexithymia in PD 545
calculation with functional MRI. Neuroimage. 1996; 3(2): 97-
103.
[82] Armitage SG. An analysis of certain psychological tests used
for the evaluation of brain injury. Psychol Monogr. 1946; 60(1,
Serial No. 277).
[83] Raven JC. Guide to using the Coloured Progressive Matrices.
London: H.K. Lewis; 1965.
[84] Mesulam MM. Attention, confusional state, and attention.
In: Mesulam MM, editor. Principles of behavioral neurology.
Philadelphia: F.A. Davis Company; 1985.
[85] Goodglass H, Kaplan E. The assessment of aphasia and related
disorders. 2nd ed., Philadelphia: Lea and Febiger; 1983.
[86] Larsen JK, Brand N, Bermond B, Hijman R. Cognitive and
emotional characteristics of alexithymia: a review of neurobi-
ological studies. J Psychosom Res. 2003; 54(6): 533-541.
[87] Bankier B, Aigner M, Bach M. Alexithymia in DSM-IV dis-
order: Comparative evaluation of somatoform disorder, pan-
ic disorder, obsessive-compulsive disorder, and depression.
Psychosomatics. 2001; 42: 235-240.
[88] Antonini A, Barone P, Marconi R, Morgante L, Zappulla S,
Pontieri F, et al. The progression of non-motor symptoms in
Parkinson’s disease and their contribution to motor disability
and quality of life. J Neurol. 2012: 1-11.
[89] Lauterbach EC. The neuropsychiatry of Parkinson’s disease.
Minerva Med. 2005; 96(3): 155-173.
